Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Evaluation of olfactory dysfunction in neurodegenerative diseases.
Epstein-Barr virus Peptide Presented by HLA-E is Predominantly Recognized by CD8(bright) Cells in multiple Sclerosis Patients.
FDA approves clinical trial of TDI-132 (Gilenya) in ALS patients
The Impact of Lesion In-Painting and Registration Methods on Voxel-Based Morphometry in Detecting Regional Cerebral Gray Matter Atrophy in Multiple Sclerosis.
Limb Apraxia in Multiple Sclerosis: Prevalence and Impact on Manual Dexterity and Activities of Daily Living.
Breastfeeding is associated with lower risk for multiple sclerosis.
Patient's Perspective: Hard Lessons from a Long Hospital Stay.
Patients feeling severely affected by multiple sclerosis: How do patients want to communicate about end-of-life issues?
The unwavering commitment of regulatory T cells in the suppression of autoimmune encephalomyelitis: Another aspect of immune privilege in the CNS.
Risk of vascular disease in patients with multiple sclerosis: a review.
Cannabinoid pharmacology: the first 66 years.
Personalized Medicine in Neurodegenerative Diseases: How Far Away?
The attributable burden of panic disorder in the impairment of quality of life in a national survey in Italy.
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients.
Long-term TENS treatment decreases cortical motor representation in multiple sclerosis.
Twin studies and the heritability of MS: a conclusion.
Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study.
Modeling the variability in brain morphology and lesion distribution in multiple sclerosis by deep learning.
Substance Name: Dronabinol
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.
160 Surgical outcomes of trigeminal neuralgia in patients with multiple sclerosis.
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.
Amelioration of experimental autoimmune encephalomyelitis by anatabine.
The role of complementary and alternative medicine in therapy of multiple sclerosis.

Pages